Mark W. Schwartz

Biography

Dr. Mark W. Schwartz, Ph.D., has been the Chief Executive Officer and President of Galena Biopharma, Inc. since August 2014. Dr. Schwartz served as the Chief Operating Officer and Executive Vice President at Galena Biopharma, Inc., since April 2011 until August 2014. Dr. Schwartz served as the Chief Executive Officer and President at Apthera, Inc. since January 2010. He served as the Chief Executive Officer and President of Bayhill Therapeutics Inc. from March 2004 to September 2009, where he complete a successful partnership with Genentech for the development of its type 1 diabetes vaccine. Dr. Schwartz served as Chief Executive Officer and President of Calyx Therapeutics, Inc., where he lead a significant fund raising round and the development of novel anti-inflammatory compounds from 2001 to 2003. For 20 years he held research, product development and senior management positions in the bioscience industry. From September 1998 to June 1999, he served as Vice President, Marketing and Business Development of Argonaut Technologies. He served as Chief Commercial Officer of LION Bioscience, Inc. and served as its Vice President - Commercial Operations since June 1999. From September 1997 to September 1998, Dr. Schwartz served as Vice President, Marketing and Business Development of Synteni Inc/Incyte Pharmaceuticals. He held senior management roles at Synteni/Incyte Genomics, Inc., where he played a key role in the successful merger of Synteni and Incyte Genomics and at Tripos, Inc., where he pioneered the Accelerated Discovery Services Business Unit and was responsible for the development of its combinatorial and drug discovery business. Earlier career positions include product management and product development positions in diagnostics at DuPont and protein instrumentation at Applied Biosytems. From 2003 to 2004, Dr. Schwartz was Managing Director of Life Sciences at Arizona Technology Enterprises. From 1989 to 1994, he held marketing positions at Biosym Technologies, Inc., which was acquired by Corning Incorporated in 1992 and Applied Biosystems Inc. From 1983 to 1989, Dr. Schwarz held research and development as well as marketing positions in the diagnostics business. He has been an Executive Director of Targazyme, Inc. since March 04, 2014. He serves as a Director of Galena Biopharma, Inc. He served as a Director at Apthera, Inc. since January 2010. He served as a Director of Bayhill Therapeutics, Inc. since April 2004. Dr. Schwartz is a Lecturer at San Jose State University. He has served on Biotechnology Industry Associations' (BIO's) Board of Directors as well as governing boards of the association's Emerging Companies Section (ECS) and Health Section, as well as the advisory board for BayBio. Dr. Schwartz holds a Ph.D. in Biochemistry from Arizona State University and received his BA in Chemistry from Grinnell College.

Research Interest

 Biochemistry